Key Takeaways
- B. Riley reduced Oklo’s price target to $92 from $129 while maintaining its Buy recommendation
- Craig-Hallum dropped its target to $71 from $87 with a Hold rating, pointing to growing capital requirements
- Needham lowered its target to $73 from $135, retaining a Buy rating with potential 20% gains ahead
- CEO Jacob Dewitte and CFO Richard Bealmear each offloaded approximately 72,000 shares at $60 per share on March 13; total insider sales reached ~$170M over 90 days
- Despite headwinds, Oklo’s Atomic Alchemy division secured a DOE Nuclear Safety Design Agreement and an NRC materials license
The past six months haven’t been kind to Oklo shareholders. Currently trading around $60.76, the nuclear energy startup has dropped 42% during this period and sits far below its 52-week peak of $193.84.
This week brought a wave of price target adjustments from multiple analyst firms following the company’s fourth quarter 2025 earnings release. While targets dropped across the board, most analysts remain constructive on the long-term story.
B. Riley reduced its price objective to $92 from $129 while maintaining a Buy recommendation. The firm highlighted meaningful business developments including DOE authorization for the Aurora facility at Idaho National Laboratory, a prepayment deal with Meta for up to 1.2 gigawatts in Ohio, initial fuel facility construction progress, and regulatory achievements at its Atomic Alchemy isotope division.
Needham similarly retained its Buy stance despite slashing its target dramatically from $135 to $73. Even at that reduced level, the new target suggests approximately 20% upside potential from current trading levels. The average analyst target currently stands around $94.80 with a “Moderate Buy” consensus view.
Craig-Hallum took a more reserved approach, maintaining its Hold rating while trimming the target from $87 to $71. The firm adjusted its financial model to reflect elevated operating costs, increased capital expenditures, and revised assumptions around future funding requirements. Additionally, it excluded anticipated 2026 isotope revenue — expected to fall under $5 million — from projections until greater visibility emerges.
Growing Capital Requirements and Executive Stock Sales Create Overhang
Oklo closed Q4 2025 with $1.4 billion in cash reserves. Following quarter-end, the company secured an additional $1.2 billion in capital. Management projects 2026 operating cash consumption of $80 million to $100 million, alongside investing cash use ranging from $350 million to $450 million.
Notwithstanding its cash position, the company recorded a trailing twelve-month EBITDA loss of $97 million and a full-year 2025 operating loss totaling $139.3 million. Wall Street analysts aren’t forecasting profitability for the current year.
Compounding investor concerns, CEO Jacob Dewitte offloaded approximately 72,960 shares on March 13 at $60 each, generating roughly $4.38 million. CFO Richard Bealmear sold 72,090 shares the same day at an identical price, netting around $4.33 million. During the trailing 90-day period, company insiders have collectively sold approximately 2.07 million shares valued at roughly $170 million. Despite these sales, insiders maintain an 18.9% ownership stake.
Regulatory Achievements Provide Bright Spots
Not all developments are negative. Oklo’s Atomic Alchemy unit obtained a DOE Nuclear Safety Design Agreement for its Groves isotopes test reactor. The division also secured an NRC materials and isotope license — marking Oklo’s first NRC license obtained via an acquired subsidiary.
The company’s Aurora reactor obtained its initial design approval from the Department of Energy, a critical milestone for advancing a 1.2-gigawatt supply agreement with Meta, with targeted delivery by 2034.
William Blair reconfirmed an Outperform rating. Cantor Fitzgerald maintained an Overweight stance with a $122 price target. Barclays holds an Overweight rating with an $82 objective. Bank of America rates the stock Buy with a $127 target.
Oklo’s 50-day moving average currently sits at $75.08, while its 200-day moving average stands at $95.27. The company’s market capitalization hovers around $9.49 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
